Concomitant immune-related events in Wilson disease: implications for monitoring chelator therapy

详细信息    查看全文

• 作者：Jessica Seessle ; Daniel Nils Gotthardt…
• 刊名：Journal of Inherited Metabolic Disease
• 出版年：2016
• 出版时间：January 2016
• 年：2016
• 卷：39
• 期：1
• 页码：125-130
• 全文大小：261 KB
• 参考文献：Bandmann O, Weiss KH, Kaler SG (2015) Wilson’s disease and other neurological copper disorders. Lancet Neurol 14(1):103–113PubMed PubMedCentral CrossRef
  Brewer GJ, Terry CA, Aisen AM, Hill GM (1987) Worsening of neurologic syndrome in patients with Wilson’s disease with initial penicillamine therapy. Arch Neurol 44:490–493PubMed CrossRef
  Czlonkowska A, Milewski B (1976) Immunological observations on patient with Wilson’s disease. J Neurol Sci 29:411–421PubMed CrossRef
  Davidson A, Diamond B (2001) Autoimmune diseases. N Engl J Med 345:340–350PubMed CrossRef
  Dourmishev LA, Stomonjakova SR, Dourmishev AL (2002) D-penicillamine induced polymyositis and morphea in a woman with Hashimoto thyroiditis. J Eur Acad Dermatol Venereol 16:538–539PubMed CrossRef
  European Association for Study of Liver (2012) EASL clinical practice guidelines: Wilson’s disease. J Hepatol 56:671–685CrossRef
  Ferenci P (2004) Review article: diagnosis and current therapy of Wilson’s disease. Aliment Pharmacol Ther 19:157–165PubMed CrossRef
  Ferenci P (2005) Wilson’s disease. Clin Gastroenterol Hepatol 3:726–733PubMed CrossRef
  Ferenci P, Caca K, Loudianos G, Mieli-Vergani G, Tanner S, Sternlieb I, Schilsky M, Cox D, Berr F (2003) Diagnosis and phenotypic classification of Wilson disease. Liver Int 23:139–142PubMed CrossRef
  Harpey JP, Caille B, Moulias R, Goust JM (1971) Lupus-like syndrome induced by d-penicillamine in Wilson’s disease. Lancet 1:292PubMed CrossRef
  Himoto T, Masaki T (2012) Extrahepatic manifestations and autoantibodies in patients with hepatitis C virus infection. Clin Dev Immunol 2012:871401PubMed PubMedCentral CrossRef
  Jaffe IA (1981) Induction of auto-immune syndromes by penicillamine therapy in rheumatoid arthritis and other diseases. Springer Semin Immunopathol 4:193–207PubMed CrossRef
  Juby AG, Davis P (1998) Prevalence and disease associations of certain autoantibodies in elderly patients. Clin Invest Med 21:4–11PubMed
  Kurien BT, Scofield RH (2006) Autoantibody determination in the diagnosis of systemic lupus erythematosus. Scand J Immunol 64:227–235PubMed CrossRef
  Liberal R, Mieli-Vergani G, Vergani D (2013) Clinical significance of autoantibodies in autoimmune hepatitis. J Autoimmun 46:17–24PubMed CrossRef
  Merle U, Schaefer M, Ferenci P, Stremmel W (2007) Clinical presentation, diagnosis and long-term outcome of Wilson’s disease: a cohort study. Gut 56:115–120PubMed PubMedCentral CrossRef
  Roath S, Wills R (1974) The effect of penicillamine on lymphocytes in culture. Postgrad Med J Suppl 2:56–59
  Roberts EA, Schilsky ML (2008) American Association for Study of Liver Diseases (AASLD). Diagnosis and treatment of Wilson disease: an update. Hepatology 47:2089–2111PubMed CrossRef
  Schaefer M, Gotthardt DN, Didion C, Stremmel W, Weiss KH (2014) Increased prevalence of subcutaneous lipomas in patients with Wilson disease. J Clin Gastroenterol
  Tan EM, Feltkamp TE, Smolen JS, Butcher B, Dawkins R, Fritzler MJ, Gordon T, Hardin JA, Kalden JR, Lahita RG, Maini RN, McDougal JS, Rothfield NF, Smeenk RJ, Takasaki Y, Wiik A, Wilson MR, Koziol JA (1997) Range of antinuclear antibodies in “healthy” individuals. Arthritis Rheum 40:1601–1611PubMed CrossRef
  Walshe JM (2007) Wilson’s disease. Lancet 369:902PubMed CrossRef
  Weiss KH, Stremmel W (2014) Clinical considerations for an effective medical therapy in Wilson’s disease. Ann N Y Acad Sci 1315:81–85PubMed CrossRef
  Weiss KH, Gotthardt DN, Klemm D, Merle U, Ferenci-Foerster D, Schaefer M, Ferenci P, Stremmel W (2011) Zinc monotherapy is not as effective as chelating agents in treatment of Wilson disease. Gastroenterology 140:1189–1198PubMed CrossRef
  Weiss KH, Thurik F, Gotthardt DN, Schäfer M, Teufel U, Wiegand F, Merle U, Ferenci-Foerster D, Maieron A, Stauber R, Zoller H, Schmidt HH, Reuner U, Hefter H, Trocello JM, Houwen RH, Ferenci P, Stremmel W (2013) Efficacy and safety of oral chelators in treatment of patients with Wilson disease. Clin Gastroenterol Hepatol 11:1028–1035.e1-2PubMed CrossRef
  
• 作者单位：Jessica Seessle (1)
  Daniel Nils Gotthardt (1) (2)
  Mark Schäfer (1)
  Annina Gohdes (1)
  Jan Pfeiffenberger (1)
  Peter Ferenci (3)
  Wolfgang Stremmel (1)
  Karl Heinz Weiss (1) (2)
  
  1. Department of Gastroenterology, University Hospital Heidelberg, Im Neuenheimer Feld 410, D-69120, Heidelberg, Germany
  2. Liver Cancer Center Heidelberg, University Hospital Heidelberg, Heidelberg, Germany
  3. Department of Gastroenterology, University Hospital Vienna, Vienna, Austria
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Internal Medicine
  Metabolic Diseases
  Human Genetics
  Biochemistry
  Pediatrics
  
• 出版者：Springer Netherlands
• ISSN：1573-2665

文摘

Background and Aims Current guidelines favor the use of chelating agents (d-penicillamine, trientine) in first line therapy of symptomatic Wilson disease patients. Development of chelator induced immunological adverse events are a concern especially under d-penicillamine therapy. This study assessed the prevalence of co-existing or therapy-related immune-mediated diseases in Wilson disease patients, and evaluated the role of antinuclear antibodies in therapy monitoring.